EMRE GÜLTEKİN · VENSA LAW

Non-Surgical Cosmetic Treatment Malpractice Lawyer in Turkey

Non-Surgical Cosmetic Treatment Malpractice in Turkey: discuss your treatment history, the documents available, and the next questions with Emre Gültekin, a lawyer at Vensa Law.

English & Turkish · Istanbul
Emre Gültekin · Vensa Law

Non-surgical describes a broad category, not a harmless procedure

A non-surgical cosmetic treatment enquiry should name the intervention before it tries to explain the outcome. Injectable treatments, skin peels, energy-based procedures and other cosmetic services do not involve the same products, equipment or clinical questions. A booking described as rejuvenation or a liquid lift may not identify what was actually done. The NHS advises that non-surgical cosmetic procedures can carry risks. The legal review should therefore examine the particular care, information and consequence rather than assume that the absence of an operation makes the concern minor or automatically straightforward.

Non-surgical aesthetic consultation — illustrative generated image
Illustrative image for this practice area.

Emre Gültekin, a lawyer at Vensa Law, can review the legal aspects of cosmetic treatment received in Turkey. The initial question may concern injury, an unexpected appearance, the product supplied or a procedure performed without adequate explanation. These issues can overlap, but need different evidence. A patient can describe the treatment in the provider's own words and identify the part they do not understand. There is no need to diagnose a product reaction or technical mistake before seeking advice. Clinical assessment is needed for medical findings and appropriate ongoing care.

Identify each treatment in a combined appointment

Several services may have been performed during one visit. Record the area and intervention for each, separating what is confirmed from what was only described commercially. A patient may have received injections and a skin treatment but been given one package invoice. Request the available clinical description rather than infer the content from the total price. If a later complication is attributed to one stage, the professional opinion should explain the basis. The fact that treatments occurred on the same day does not prove they all caused the same effect.

The chronology should also include earlier and later procedures in the relevant area. Another treatment may be important to interpretation without automatically resolving the original provider's responsibility. If records use different names, preserve both versions and seek clarification. Do not replace the provider's terminology with a more serious-sounding procedure that has not been verified. A clear treatment map can identify the questions for an independent clinician, including which records are needed to assess the relationship between the interventions and the present condition. It can also prevent a claim being directed at the wrong service.

Distinguish botulinum toxin from filler

A patient may use Botox as a general word for facial injections, but the actual product should be identified. Botulinum toxin and dermal fillers are different categories, and their records should not be treated as interchangeable. The NHS's advice on choosing a cosmetic practitioner distinguishes them and emphasises knowing the product and people involved. Its UK prescription and registration rules should not be imported as Turkish law. In a Turkish matter, the actual substance, relevant permissions and professional roles require examination under the rules applicable to the treatment.

Ask for the product name, available identifiers and treatment record. If the patient remembers only a box or syringe, preserve the photograph and explain its source without assuming it proves what was administered. A promotional list of products stocked by the clinic may not identify the product used on this occasion. Equally, the absence of a box photograph does not prevent review. The provider's records and explanation may help establish the details. The legal enquiry should distinguish uncertainty about identity from evidence that an unauthorised or different product was supplied.

Product identity and clinical performance are separate questions

An authentic product can still be part of disputed care, and a concern about appearance does not itself show that the product was counterfeit. Where authenticity, storage or supply is questioned, identify the actual evidence and who supplied the information. Batch or lot details and the clinic's records may be relevant. A clinician or other appropriately qualified professional can explain the significance of technical material. A lawyer should not declare a product defective from a misspelled marketing message or a photograph whose connection with the treatment is uncertain.

Foreign regulatory approval should also be described accurately. The US FDA's information about fillers is useful for medical risk awareness, but FDA approval does not determine whether a product was lawfully supplied or used in Turkey. The applicable Turkish position needs its own assessment. The same caution applies to brand claims about certification. Establish what certification is being asserted, what it covers and its relevance to the actual product or facility. Product-related allegations and allegations about the practitioner's choices may involve different responsibilities and should not be merged without supporting evidence.

Filler concerns can involve more than unwanted volume

A patient may report a lump, a change in colour, pain, altered appearance or a later recommendation for further care. Those descriptions should be recorded with timing and location, not treated as a complete diagnosis. FDA information identifies potentially serious complications from unintended injection into a blood vessel. That general risk does not establish what occurred in the individual case. A relevant clinician should assess symptoms and findings. The legal review can then distinguish the original intervention, recognition of a problem and the response to it.

Current severe or unexpected symptoms, particularly visual changes, need prompt medical assessment. Evidence gathering should not delay care, and this page does not give instructions for dissolving filler or managing a reaction. The FDA also explains that removal can be difficult and has its own risks. An offer to reverse the treatment should therefore not be described as an automatic return to the starting position. Obtain appropriate clinical advice about any proposal. Preserve examination findings, interventions and reasons so that later legal analysis can consider the actual course rather than assumptions about reversibility.

Review botulinum toxin concerns through the actual record

Where a patient reports an unwanted change after botulinum toxin treatment, identify the treated areas, the product and the recorded plan. The patient's description of movement, symmetry or everyday difficulty is useful, but should be separated from a clinical conclusion about dose, placement or cause. Different products or units should not be compared by the patient as though the numbers necessarily meant the same thing. Any technical interpretation belongs with an appropriate professional. The legal assessment should not infer an error from the treatment's price or the number written on a sales receipt alone.

The response to the concern is also important. Who assessed the patient, what was found and what advice or further intervention followed? Keep subsequent records rather than summarise everything as the treatment went wrong. If the provider suggested waiting, identify which concern was discussed and whether a clinical assessment accompanied that advice. Current health concerns require suitable medical attention. The review should distinguish a disagreement about the desired cosmetic effect from a supported allegation of harmful care, while recognising that both can be significant to the patient's circumstances.

Peels and energy-based services require different technical records

For a chemical peel, relevant information may include the actual product and documented application. For an energy-based procedure, identify the device and available treatment record. Patients should request existing information rather than presume that every facility has the same records. The FDA warns of serious skin injuries from certain peel products used without appropriate professional supervision. Its warning provides risk context; it does not diagnose a particular burn or establish a Turkish licensing rule. Individual findings and the precise intervention need assessment before a technical allegation is advanced.

If the concern is a burn, pigment change, scarring or another skin effect, preserve the timeline and the clinician's description. Do not diagnose depth or permanence from a phone image. A before-and-after photograph may show a change but cannot explain every cause. Ask the later professional to distinguish current care recommendations from a retrospective view of the original service. The same approach applies when several sessions were sold: identify the session after which the concern arose, any changes in the plan and what happened to remaining appointments or prepaid services.

The assessment and consent should reflect the actual intervention

The original consultation can help establish the objective, relevant history and options discussed. A general skin analysis or online recommendation may differ from the assessment made immediately before treatment. Preserve both where available. If the service changed during the appointment, identify who proposed the change and what explanation was given. A consent form for one treatment should not automatically be read as consent to every intervention offered that day. Conversely, a recorded explanation and agreement should be included even if the patient now regrets the decision.

Turkish patient rights rules address information and informed consent. Language, timing and the patient's opportunity to understand may be relevant in an international enquiry. A lawyer can examine the decision process while a clinician explains the significance of omitted or disputed information. A general warning that all cosmetic care carries risks does not itself resolve a specific consent concern. Equally, an adverse result does not establish that no information was given. The evidence should identify the actual discussion, documents and material change rather than rely solely on competing general statements.

Advertising and photographic promises need their context

A claim of no downtime, guaranteed symmetry or complete reversal should be preserved in its original wording if it influenced the decision. Identify whether it was general advertising or a personalised assurance. An image may be edited, simulated or unrelated to the particular product. That does not automatically determine a legal claim, but it matters to interpretation. Save the original offer and the consultation explanation. The review should not turn a qualified example into an unqualified promise, or discard a clear individual commitment because the package also contained general disclaimers.

Patient photographs should retain their dates and sources. Lighting, facial expression, makeup and later treatments can affect comparison. Explain important differences rather than adjust images to strengthen an allegation. A clinician can state what the pictures support and what requires examination. If the clinic published an image of the patient, distinguish that publication from the clinical record and preserve the version actually shown. A visual discrepancy may raise a question about marketing or documentation, while the condition and cause still need their own assessment. Each use of the photograph should be clear.

Establish the practitioner, setting and service relationship

A cosmetic treatment may be arranged through a clinic, dental practice, beauty business, hotel visit or intermediary. The actual setting and activity must be established before authorisation or responsibility is assessed. A commercial certificate or social media description should not be assumed to establish lawful professional scope. The provider's identity, qualifications and permitted activity need Turkish rules relevant to the date. A foreign licensing scheme is not a substitute. The agreement and clinical record should also show who selected the treatment and who actually performed it.

Payment to an organiser may not identify the person responsible for clinical decisions. Keep the invoice, payment evidence and communications explaining the service. Where a particular clinician was promised, preserve that commitment and the information about any substitution. A regulatory concern does not automatically prove the cause of an injury, and a qualified title does not settle whether the actual care was appropriate. The legal review should distinguish these questions and examine the evidence for each. Patients can supply the names available without having to resolve the provider's corporate structure themselves.

Further treatment and financial claims need reasons

A top-up, removal, repeat peel or different device session may be offered as correction. Clarify the intended benefit, clinical suitability and limitations. The proposal may address appearance without resolving a separate health concern. Free treatment is not automatically appropriate or an admission of fault. A release or settlement has its own legal effect and should be considered separately. A patient's objective may be an explanation or independent assessment rather than another intervention, and that preference should be identified accurately when options are discussed.

Keep the costs of examinations, care and other relevant consequences with supporting records. Separate completed expenses from estimates and optional changes. The package price or number of injections does not create a standard compensation entitlement. Responsibility, causation and recoverable loss need individual analysis. A complaint, product enquiry and damages claim can serve different purposes, while informal repair discussions should not be assumed to suspend legal time limits. The relevant dates should be reviewed promptly. No website can responsibly promise a particular financial outcome from a description or photograph alone.

Discuss the particular treatment with Vensa Law

An initial account can identify the procedure as described, date, setting, areas treated and present concern. Include useful product or device information, the agreed objective and any later clinical opinion. State whether further intervention is scheduled. Distinguish personal observations from professional findings and identify uncertain information openly. The review can determine which questions concern the agreement, the clinical course, the product or the relevant legal process. A patient does not need to choose a final claim category before asking for guidance about treatment in Turkey.

Emre Gültekin works as a lawyer at Vensa Law. Firm information is available at https://vensalaw.com/; enquiries can be made on +905369968588 or through [email protected]. The scope of work and records required can be discussed for the individual matter. Advice should explain the evidence, its limitations and the available options. An initial review does not guarantee compensation, a finding of negligence or a successful corrective procedure. The actual service and its documented consequences remain the basis of the assessment, regardless of how simple or advanced the treatment was advertised to be.

Official information and sources

Emre Gültekin · Vensa Law

VENSA LAW

Emre Gültekin

Emre Gültekin is a lawyer at Vensa Law, an Istanbul-based legal team. You can speak with Emre about your own experience while drawing on the firm’s wider team and shared office. The proposed work, responsibilities and terms of representation are discussed for the individual matter.

YOUR QUESTIONS

Before the first conversation.

Are botulinum toxin and dermal filler the same treatment?

No. Identify the actual product and intervention rather than use a general injection label. Their clinical questions and relevant records may differ.

Does non-surgical mean a complication is legally minor?

No. The actual care, consequences and evidence matter. The absence of an operation does not determine responsibility or the seriousness of an individual concern.

Does foreign regulatory approval prove a product was lawful in Turkey?

No. Foreign information may provide context, but the applicable Turkish product and professional rules require their own assessment.

Does an offer to remove filler guarantee a return to the starting position?

No. Removal has limitations and risks requiring individual clinical assessment. Its legal terms should be considered separately from the medical proposal.

Can one package invoice identify every treatment I received?

Not necessarily. Ask for the available clinical description of each intervention, area, product or device, and identify the actual providers.

YOUR FIRST CONVERSATION

Tell Emre about your legal matter.

A short account is enough to start. Include a reliable way to contact you, and the office will explain what information may be useful next.

This website provides general information. Sending an inquiry does not create an attorney–client relationship. Any proposed representation and its terms are discussed individually.

~1 Hour Response Time